FDA Finds No Risk of Death Linked to Paclitaxel-Coated Balloons and Stents
The FDA has reversed its opinion on paclitaxel-coated balloons and stents, saying they no longer believe the implants increase the risk of death for patients.
The FDA has reversed its opinion on paclitaxel-coated balloons and stents, saying they no longer believe the implants increase the risk of death for patients.
The FDA is calling for clinical trials to continue, with some precautions, into potential mortality risks linked to balloons and stents coated with paclitaxel.
The FDA is warning that paclitaxel-coated stents and balloons appear to significantly increase the risk of patients' deaths.
Use of the chemotherapy drug Taxol (paclitaxel) may significantly increase the risk of chronic neuropathic pain in breast cancer survivors, according to a new study from U.S. researchers.